Standard

Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. / Miroshnichenko, Svetlana; Patutina, Olga; Almieva, Olga et al.

In: International Journal of Molecular Sciences, Vol. 27, No. 12, 5446, 17.06.2026.

Research output: Contribution to journal › Article › peer-review

Harvard

APA

Vancouver

Miroshnichenko S, Patutina O, Almieva O, Burakova E, Maslov M, Fokina A et al. Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. International Journal of Molecular Sciences. 2026 Jun 17;27(12):5446. doi: 10.3390/ijms27125446

Author

Miroshnichenko, Svetlana ; Patutina, Olga ; Almieva, Olga et al. / Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. In: International Journal of Molecular Sciences. 2026 ; Vol. 27, No. 12.

BibTeX

@article{8a05739a033543429cdd7c6f31021e9d,
title = "Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides",
abstract = "Molecular heterogeneity of malignant tumours remains a central challenge in oncology. Although neoplasms of distinct histogenesis share core oncogenic properties, the signalling networks sustaining these phenotypes are tumour-specific, highlighting the need for regulatory-level therapeutics adaptable to distinct molecular contexts. Oncogenic microRNAs (miRNAs), among which miR-21, miR-17, and miR-155 are broadly overexpressed in epithelial, lymphoid, and glial-neuronal neoplasms, represent attractive targets for therapeutic intervention. MiRNA inhibition by antisense oligonucleotides has emerged as a promising therapeutic strategy, and mesyl (methanesulfonyl) phosphoramidate oligonucleotides (µ-AMOs) represent a next-generation class of anti-miRNA agents with superior nuclease resistance and biological activity. Here, we report a systematic screening of 23 tumour cell lines of diverse histogenesis for sensitivity to paired combinations of µ-AMOs targeting miR-21, miR-17, and miR-155. Epithelial-derived lines exhibited the highest responsiveness, while lymphoid cell lines demonstrated the lowest sensitivity. The efficacy of specific µ-AMO pairs was found to be cell type-specific: combinations containing miR-21-targeting µ-AMO were most effective in epithelial lines, whereas the miR-17/miR-155-targeting pair showed superior activity in neuroglial models. Cellular responsiveness was driven by the extent of miRNA suppression, with no correlation detected for delivery efficiency or basal miRNA levels. The obtained results provide a basis for tumour-type-specific selection of µ-AMO combinations for clinical translation.",
keywords = "anti-miRs, antisense oligonucleotides, cancer, epithelial tumour cells, lymphoid tumour cells, mesyl phosphoramidate, miR-155, miR-17, miR-21, neuronal tumour cells, рак, эпителиальные опухолевые клетки, нейрональные опухолевые клетки, лимфоидные опухолевые клетки, антисмысловые олигонуклеотиды, анти-микроРНК, miR-21, miR-17, miR-155, мезилфосфорамидат",
author = "Svetlana Miroshnichenko and Olga Patutina and Olga Almieva and Ekaterina Burakova and Mikhail Maslov and Alesya Fokina and Dmitry Stetsenko and Marina Zenkova",
note = "Miroshnichenko, S.; Patutina, O.; Almieva, O.; Burakova, E.; Maslov, M.; Fokina, A.; Stetsenko, D.; Zenkova, M. Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. Int. J. Mol. Sci. 2026, 27, 5446. https://doi.org/10.3390/ijms27125446 This research was funded by the Russian Science Foundation, grant #25-14-00171 and the Russian state-funded project for ICBFM SB RAS #125012300659-6.",
year = "2026",
month = jun,
day = "17",
doi = "10.3390/ijms27125446",
language = "English",
volume = "27",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

RIS

TY - JOUR

T1 - Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides

AU - Miroshnichenko, Svetlana

AU - Patutina, Olga

AU - Almieva, Olga

AU - Burakova, Ekaterina

AU - Maslov, Mikhail

AU - Fokina, Alesya

AU - Stetsenko, Dmitry

AU - Zenkova, Marina

N1 - Miroshnichenko, S.; Patutina, O.; Almieva, O.; Burakova, E.; Maslov, M.; Fokina, A.; Stetsenko, D.; Zenkova, M. Panel-Wide Screening of Tumour Cells of Diverse Histogenesis for Responsiveness to Silencing of miR-21, miR-17, and miR-155 by Mesyl Phosphoramidate Antisense Oligonucleotides. Int. J. Mol. Sci. 2026, 27, 5446. https://doi.org/10.3390/ijms27125446 This research was funded by the Russian Science Foundation, grant #25-14-00171 and the Russian state-funded project for ICBFM SB RAS #125012300659-6.

PY - 2026/6/17

Y1 - 2026/6/17

N2 - Molecular heterogeneity of malignant tumours remains a central challenge in oncology. Although neoplasms of distinct histogenesis share core oncogenic properties, the signalling networks sustaining these phenotypes are tumour-specific, highlighting the need for regulatory-level therapeutics adaptable to distinct molecular contexts. Oncogenic microRNAs (miRNAs), among which miR-21, miR-17, and miR-155 are broadly overexpressed in epithelial, lymphoid, and glial-neuronal neoplasms, represent attractive targets for therapeutic intervention. MiRNA inhibition by antisense oligonucleotides has emerged as a promising therapeutic strategy, and mesyl (methanesulfonyl) phosphoramidate oligonucleotides (µ-AMOs) represent a next-generation class of anti-miRNA agents with superior nuclease resistance and biological activity. Here, we report a systematic screening of 23 tumour cell lines of diverse histogenesis for sensitivity to paired combinations of µ-AMOs targeting miR-21, miR-17, and miR-155. Epithelial-derived lines exhibited the highest responsiveness, while lymphoid cell lines demonstrated the lowest sensitivity. The efficacy of specific µ-AMO pairs was found to be cell type-specific: combinations containing miR-21-targeting µ-AMO were most effective in epithelial lines, whereas the miR-17/miR-155-targeting pair showed superior activity in neuroglial models. Cellular responsiveness was driven by the extent of miRNA suppression, with no correlation detected for delivery efficiency or basal miRNA levels. The obtained results provide a basis for tumour-type-specific selection of µ-AMO combinations for clinical translation.

AB - Molecular heterogeneity of malignant tumours remains a central challenge in oncology. Although neoplasms of distinct histogenesis share core oncogenic properties, the signalling networks sustaining these phenotypes are tumour-specific, highlighting the need for regulatory-level therapeutics adaptable to distinct molecular contexts. Oncogenic microRNAs (miRNAs), among which miR-21, miR-17, and miR-155 are broadly overexpressed in epithelial, lymphoid, and glial-neuronal neoplasms, represent attractive targets for therapeutic intervention. MiRNA inhibition by antisense oligonucleotides has emerged as a promising therapeutic strategy, and mesyl (methanesulfonyl) phosphoramidate oligonucleotides (µ-AMOs) represent a next-generation class of anti-miRNA agents with superior nuclease resistance and biological activity. Here, we report a systematic screening of 23 tumour cell lines of diverse histogenesis for sensitivity to paired combinations of µ-AMOs targeting miR-21, miR-17, and miR-155. Epithelial-derived lines exhibited the highest responsiveness, while lymphoid cell lines demonstrated the lowest sensitivity. The efficacy of specific µ-AMO pairs was found to be cell type-specific: combinations containing miR-21-targeting µ-AMO were most effective in epithelial lines, whereas the miR-17/miR-155-targeting pair showed superior activity in neuroglial models. Cellular responsiveness was driven by the extent of miRNA suppression, with no correlation detected for delivery efficiency or basal miRNA levels. The obtained results provide a basis for tumour-type-specific selection of µ-AMO combinations for clinical translation.

KW - anti-miRs

KW - antisense oligonucleotides

KW - cancer

KW - epithelial tumour cells

KW - lymphoid tumour cells

KW - mesyl phosphoramidate

KW - miR-155

KW - miR-17

KW - miR-21

KW - neuronal tumour cells

KW - рак

KW - эпителиальные опухолевые клетки

KW - нейрональные опухолевые клетки

KW - лимфоидные опухолевые клетки

KW - антисмысловые олигонуклеотиды

KW - анти-микроРНК

KW - miR-21

KW - miR-17

KW - miR-155

KW - мезилфосфорамидат

UR - https://www.mendeley.com/catalogue/1174a743-dc53-310f-82d7-73ab343f2583/

UR - https://www.scopus.com/pages/publications/105043086158

U2 - 10.3390/ijms27125446

DO - 10.3390/ijms27125446

M3 - Article

C2 - 42353165

VL - 27

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

M1 - 5446

ER -

ID: 85413440